Biohaven Ltd. (NYSE: BHVN) announced the completion of enrollment in its Phase 2 study evaluating taldefgrobep alfa for obesity treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE